UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 18, 2011
BIOCUREX, INC.
-------------------------------
(Exact name of Registrant as specified in its charter)
Texas 0-269471 75-2742601
-------------------- --------------------- ------------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
7080 River Road, Suite 215,
Vancouver, British Columbia, Canada, V6X 1X5
--------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (866) 884-8669
N/A
-----------------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors of Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of
Certain Officers.
On July 18, 2011 the Company appointed Paul D. Slowey, Ph.D. as President
and a Director and appointed Trent Davis as a Director.
Dr. Paul Slowey (age 55) has been President and Chief Executive Officer of
Oasis Diagnostics Corporation since 2007 and Managing Member of Bamburgh Marrsh
LLC since 2002. Previously he held various diagnostic positions including;
Director of International Sales for OraSure (formerly Epitope), Chief Operating
Officer for Saliva Diagnostics, Director of International Sales for Incstar
Corp. [now DiaSorin]. He holds a B.S. (Honors) from Sheffield Polytechnic
(England), a Ph.D. in Organic Chemistry from the University of
Newcastle-Upon-Tyne (England) and Post-Doctoral Fellowships from University of
Victoria and Memorial University of Newfoundland (Canada).
As President, Dr. Slowey will be responsible for marketing and management
of the Company's OncoPet Diagnostics Division and supporting the broader
licensing efforts of the Company. Dr. Slowey served as the Company's Chief
Executive Officer during 2001-2002 and has been a consultant to the Company for
the past three years.
Trent Davis (age 43) has been with Paulson Investment Company, Inc. since
1991 and has served as Paulson's President and Chief Executive Officer since
2005. Prior to being appointed as President and Chief Executive Officer, Mr.
Davis served as Senior Vice President of Paulson's Syndicate Department. From
2001 to 2005 Mr. Davis served as a board member of the National Investment
Banking Association and from 2003 to 2004 Mr. Davis served as Chairman of that
association. Mr. Davis holds a B.S. in Business and Economics from Linfield
College and earned a Master's Degree in Business Administration from the
University of Portland.
As head of the Syndicate Department for Paulson financings, Mr. Davis was
intimately involved in the financing of the Company in January 2010. As a
Director, Mr. Davis brings extensive experience in capital markets and investor
relations to the Company.
As of July 18, 2011 Dr. Slowey did not own any shares of the Company's
common stock.
As of July 18, 2011 Mr. Davis owned 20,000 shares of the Company's common
stock. These shares represent 0.01% of the Company's outstanding shares as of
July 18, 2011. As of July 18, 2011 Mr. Davis also owned warrants which allow Mr.
Davis to purchase up to 200,000 shares of the Company's common stock at a price
of $0.107 per share. The warrants expire on January 19, 2015.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 22, 2011
BIOCUREX, INC.
By: /s/ Ricardo Moro
---------------------------
Dr. Ricardo Moro, President
3
